Table 2.
Demographic and Clinical Characteristics of the Subgroups of Patients by Medication Class
| Medication Class | Sample Size, n | Age, Years, Mean ± SD | Female, n | No. of Previous Depressive Episodes, Mean ± SD | HAM-D Baseline, Mean ± SD | HAM-D 7 Days, Mean ± SD |
|---|---|---|---|---|---|---|
| SSRI (Citalopram, Escitalopram, Paroxetine, Sertraline) | 13 | 29.9 ± 10.0 | 8 | 0.6 ± 0.8 | 19.7 ± 4.2 | 13.9 ± 4.6 |
| TCA (Trimipramine, Amitriptyline, Amitriptylinoxide) | 8 | 36.6 ± 11.9 | 4 | 2.1 ± 1.1 | 22.1 ± 3.4 | 16.6 ± 5.5 |
| NDRI (Bupropion) | 6 | 30.7 ± 10.5 | 3 | 0.7 ± 0.5 | 18.5 ± 3.5 | 17.8 ± 3.2 |
| SNRI (Venlafaxine, Duloxetine) | 6 | 31.7 ± 10.9 | 2 | 1.7 ± 0.8 | 18.3 ± 2.5 | 14.7 ± 5.5 |
| NaSSA (Mirtazapine) | 5 | 26.8 ± 6.1 | 3 | 2.6 ± 3.2 | 20.2 ± 4.8 | 13.8 ± 4.7 |
| REM Suppressive (SSRI, SNRI, Amitriptylin, Amitriptylinoxide) | 21 | 31.1 ± 10.3 | 11 | 1.1 ± 1.0 | 19.2 ± 3.6 | 14.1 ± 4.5 |
| REM Nonsuppressive | 17 | 31.6 ± 10.4 | 7 | 1.7 ± 2.0 | 20.7 ± 4.1 | 16.6 ± 4.9 |
The NaSSA subgroup was not analyzed separately due to a small sample size.
HAM-D, Hamilton Depression Rating Scale; NaSSA, noradrenergic and specific serotonergic antidepressant; NDRI, norepinephrine-dopamine reuptake inhibitor; REM, rapid eye movement; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.